Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet What is cagrisema and how does it work for weight loss? CagriSema 2026: Everything You Need to Know About the Next Gen Weight Loss Combination Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination